News | August 31, 2025
Novo Nordisk taps Replicate Bioscience’s srRNA platform for obesity
Replicate will receive research funding and could potentially receive up to approximately US$550 million
Replicate will receive research funding and could potentially receive up to approximately US$550 million
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
The accelerated approval is supported by results from part 1 of the ESSENCE trial
These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
The submission is based on data from the STEP UP and STEP UP T2D clinical trials
The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
Subscribe To Our Newsletter & Stay Updated
